Scientech Research LLC Buys New Stake in Sarepta Therapeutics, Inc. $SRPT

Scientech Research LLC purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The firm purchased 15,163 shares of the biotechnology company's stock, valued at approximately $968,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. EP Wealth Advisors LLC lifted its stake in Sarepta Therapeutics by 2.2% in the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock valued at $606,000 after buying an additional 105 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Sarepta Therapeutics by 4.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,699 shares of the biotechnology company's stock valued at $571,000 after buying an additional 218 shares in the last quarter. UMB Bank n.a. lifted its stake in Sarepta Therapeutics by 53.0% in the 1st quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company's stock valued at $51,000 after buying an additional 276 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in Sarepta Therapeutics by 2.6% in the 1st quarter. State of Alaska Department of Revenue now owns 11,175 shares of the biotechnology company's stock valued at $713,000 after buying an additional 285 shares in the last quarter. Finally, State of Michigan Retirement System lifted its stake in Sarepta Therapeutics by 1.3% in the 1st quarter. State of Michigan Retirement System now owns 22,900 shares of the biotechnology company's stock valued at $1,461,000 after buying an additional 300 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Barclays raised shares of Sarepta Therapeutics from an "underweight" rating to an "equal weight" rating and set a $22.00 price target on the stock in a research note on Tuesday, July 29th. Robert W. Baird increased their price objective on shares of Sarepta Therapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Cantor Fitzgerald reiterated a "neutral" rating on shares of Sarepta Therapeutics in a report on Monday, June 16th. Sanford C. Bernstein began coverage on shares of Sarepta Therapeutics in a report on Tuesday, July 29th. They issued a "market perform" rating and a $13.00 price objective for the company. Finally, JPMorgan Chase & Co. upgraded shares of Sarepta Therapeutics from an "underweight" rating to a "neutral" rating and set a $24.00 price objective for the company in a report on Tuesday, July 29th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $42.36.

Sarepta Therapeutics Trading Down 2.9%

Shares of NASDAQ SRPT traded down $0.52 during midday trading on Friday, reaching $17.39. 3,492,616 shares of the stock were exchanged, compared to its average volume of 7,880,755. The company has a 50 day simple moving average of $17.75 and a 200 day simple moving average of $40.83. The stock has a market capitalization of $1.70 billion, a P/E ratio of -19.99 and a beta of 0.49. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. Sarepta Therapeutics, Inc. has a twelve month low of $10.41 and a twelve month high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. The business had revenue of $611.09 million during the quarter, compared to the consensus estimate of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business's revenue was up 68.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.07 EPS. As a group, equities analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.